Glenmark Pharmaceuticals Limited (IN:GLENMARK)
:GLENMARK
Want to see IN:GLENMARK full AI Analyst Report?
Top Page
Glenmark Pharmaceuticals Limited
(GLENMARK)
Select Model
Select Model
Rating:53Neutral
Price Target:
₹2,442.00
▲(18.20% Upside)
Action:ReiteratedDate:11/01/25
Glenmark Pharmaceuticals' overall stock score is primarily influenced by financial performance challenges, including profitability volatility and liquidity concerns. The technical analysis suggests bearish momentum, and the high P/E ratio indicates overvaluation. These factors collectively contribute to a moderate stock score.
Positive Factors
Strong Revenue Growth
Sustained ~25% revenue growth indicates expanding market penetration and product adoption across geographies. Over 2–6 months this supports scale economies, funds reinvestment in R&D and manufacturing, and provides a structural runway to improve margins if cash conversion and cost discipline follow.
Negative Factors
High Leverage
Elevated debt relative to equity is a persistent structural risk: it increases interest burden, limits strategic flexibility and raises refinancing risk if cash generation falters. Over months this constrains capital allocation for M&A, capex or R&D until leverage is meaningfully reduced.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Sustained ~25% revenue growth indicates expanding market penetration and product adoption across geographies. Over 2–6 months this supports scale economies, funds reinvestment in R&D and manufacturing, and provides a structural runway to improve margins if cash conversion and cost discipline follow.
Read all positive factors
Glenmark Pharmaceuticals Limited (GLENMARK) vs. iShares MSCI India ETF (INDA)
Market Cap
₹678.85B
Dividend Yield0.24%
Average Volume (3M)28.97K
Price to Earnings (P/E)35.6
Beta (1Y)0.51
Revenue Growth25.44%
EPS GrowthN/A
CountryIN
Employees14,989
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)14.28
Shares Outstanding282,200,800
10 Day Avg. Volume44,119
30 Day Avg. Volume28,971
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.81
Price to Sales (P/S)3.19
P/FCF Ratio-27.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,940.00Price Target Upside-6.10% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)81.77
Revenue Forecast (FY)₹159.47B
Glenmark Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulation...
How the Company Makes Money
Glenmark primarily makes money by selling pharmaceutical products and related services across geographies, with revenue generated from (1) finished-dosage formulations sold under branded and/or generic portfolios in key markets, (2) sales of activ...
Glenmark Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 159.26B | 133.63B | 126.45B | 116.56B | 123.05B | 109.44B |
| Gross Profit | 91.81B | 88.38B | 80.66B | 72.45B | 77.57B | 70.97B |
| EBITDA | 25.04B | 21.68B | 18.30B | 14.29B | 19.12B | 19.45B |
| Net Income | 10.10B | 10.47B | -15.02B | 2.97B | 9.42B | 9.70B |
Balance Sheet | ||||||
| Total Assets | 190.02B | 160.50B | 143.59B | 193.72B | 170.83B | 156.04B |
| Cash, Cash Equivalents and Short-Term Investments | 29.58B | 17.12B | 16.64B | 11.73B | 14.43B | 11.47B |
| Total Debt | 12.24B | 24.73B | 12.31B | 46.08B | 39.62B | 49.86B |
| Total Liabilities | 94.20B | 72.00B | 65.11B | 95.32B | 76.45B | 85.39B |
| Stockholders Equity | 95.82B | 88.49B | 78.48B | 94.74B | 90.87B | 70.65B |
Cash Flow | ||||||
| Free Cash Flow | 23.35B | -15.77B | -11.64B | 176.29M | 3.19B | 3.56B |
| Operating Cash Flow | 28.36B | -8.28B | -2.65B | 6.25B | 11.09B | 11.31B |
| Investing Cash Flow | -5.02B | 20.94M | 45.44B | -5.28B | -3.33B | -6.75B |
| Financing Cash Flow | -14.90B | 7.87B | -39.06B | -774.56M | -5.20B | -4.42B |
Glenmark Pharmaceuticals Limited Technical Analysis
Positive
2065.95
Price Trends
2101.64
Positive
2040.55
Positive
2003.56
Positive
Market Momentum
32.22
Negative
61.57
Neutral
92.94
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLENMARK, the sentiment is Positive. The current price of 2065.95 is below the 20-day moving average (MA) of 2156.98, below the 50-day MA of 2101.64, and above the 200-day MA of 2003.56, indicating a bullish trend. The MACD of 32.22 indicates Negative momentum. The RSI at 61.57 is Neutral, neither overbought nor oversold. The STOCH value of 92.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLENMARK.
Glenmark Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹807.05B | 18.87 | ― | 0.33% | 7.31% | 0.34% | |
72 Outperform | ₹646.14B | 25.97 | ― | 0.80% | 11.73% | 10.02% | |
72 Outperform | ₹1.05T | 20.49 | ― | 0.57% | 18.86% | 61.69% | |
63 Neutral | ₹582.23B | 91.56 | ― | 0.12% | 13.99% | -27.80% | |
63 Neutral | ₹395.66B | 35.44 | ― | 2.16% | 2.59% | 18.83% | |
53 Neutral | ₹678.85B | 35.61 | ― | 0.24% | 25.44% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,405.55
1,033.27
75.30%
IN:ALKEM
Alkem Laboratories Ltd.
5,404.05
341.47
6.74%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,389.55
181.98
15.07%
IN:BIOCON
Biocon Limited
359.55
41.33
12.99%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,335.60
-480.20
-17.05%
IN:LUPIN
Lupin Limited
2,303.70
258.61
12.65%
Glenmark Pharmaceuticals Limited Corporate Events
Glenmark Launches Low-Cost Semaglutide GLIPIQ in India to Expand Diabetes Care
Mar 20, 2026
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 diabetes, aiming to make GLP-1 therapy significantly more affordable and accessible. The product, approved by the Central Drugs Standard Control Organ...
Glenmark launches low-cost semaglutide GLIPIQ in India to widen diabetes care access
Mar 20, 2026
Glenmark Pharmaceuticals has launched GLIPIQ (semaglutide) in India for the management of Type 2 Diabetes Mellitus, positioning it as a significantly more affordable GLP-1 therapy to widen access to advanced injectable treatment. Approved by the C...
Glenmark Wins U.S. FDA Nod and 180-Day Exclusivity for Generic FloVent Inhaler
Mar 4, 2026
Glenmark Specialty SA, a unit of Glenmark Pharmaceuticals, has received final U.S. FDA approval for its Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, deemed bioequivalent and therapeutically equivalent to GlaxoSmithKlineR...
Glenmark to Enter $66.8 Million U.S. Sodium Phosphates Injection Market in April
Feb 27, 2026
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., will launch Sodium Phosphates Injection USP in three single-dose vial strengths that are bioequivalent and therapeutically equivalent to Hospira Inc.’s refere...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.